Download Supplementary material for

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
page
9
page
10
page
11
page
12
page
13
page
14
page
15
page
16
page
17
page
18
page
19
page
20
page
21
page
22
page
23
page
24
page
25
page
26
Document related concepts
no text concepts found
Transcript 
760
Interim analysis after 340 deaths: HR of
death 1.40 in experimental arm (P=0.002);
OS 10.8 mos (standard arm) vs. 7.7 mos
(experimental arm)
7
Unselected, stage
IIIB/IV
Erlotinib followed at progression
by Cisplatin-Gemcitabine
(experimental arm) vs. CisplatinGemcitabine followed at
progression by Erlotinib
(standard arm)
Cisplatin-Gemcitabine ±
Gefitinib
1,093
8
INTACT-2
Unselected, stage
IIIB/IV
Carboplatin-Paclitaxel ±
Gefitinib
1,037
IPASS
East Asian, nonor former light
smoker, stage
IIIB/IV, adenoca
Stage IIIB/IV,
EGFR mutant in
Japan
Korean, neversmoker, stage
IIIB/IV
Stage IIIB/IV,
EGFR mutant in
Japan
Gefitinib vs.
Carboplatin-Paclitaxel
1,217
OS 9.9 mos (gefitinib 500 mg/d) vs. 9.9 mos
(Gefitinib 250 mg/d) vs. 10.9 mos (placebo)
(P=0.46)
OS 8.7 mos (gefitinib 500 mg/d) vs. 9.8 mos
(gefitinib 250 mg/d) vs. 9.9 mos (placebo)
(P=0.64)
PFS: 12-mo PFS rate 24.9% (gefitinib) vs.
6.7% (chemo) (P<0.001)
Gefitinib vs. Cisplatin-Docetaxel
172
PFS 9.2 mos (Gefitinib) vs. 6.3 mos (chemo)
(P<0.001)
11
Gefitinib vs. CisplatinGemcitabine
313
OS 20.3 mos (Gefitinib) vs. 23.1 mos
(chemo) (P=0.43)
12
Gefitinib vs. CarboplatinPaclitaxel
200
13
EGFR+, stage
IIIB/IV
Unselected, stage
IIIB/IV
Cisplatin-Vinorelbine ±
Cetuximab
Carboplatin-Taxane ±
Cetuximab
1,125
Unselected, stage
IV or recurrent
disease after prior
surgery and/or
irradiation
Carboplatin-PaclitaxelBevacizumab ± Cetuximab
Enrolling
PFS 10.8 mos (gefitinib) vs. 5.4 mos (chemo
alone) (P<0.001)
[Secondary endpoints: RR 73.7% (Gefitinib)
vs. 30.7% (chemo) (P<0.001); OS 30.5 mos
(Gefitinib) vs. 23.6 mos (chemo) (P=0.31)
OS 11.3 mos (chemo + Cetuximab) vs. 10.1
mos (chemo alone) (P=0.04)
PFS 4.4 mos (chemo + Cetuximab) vs. 4.24
mos (chemo alone) (P=0.236) [Secondary
endpoint OS 9.69 mos (chemo + Cetuximab)
vs. 8.38 mos (chemo alone) (P=0.169)
OS and PFS
Unselected, stage
4 cycles platinum doublet
889
PFS 12.3 weeks (Erlotinib) vs. 11.1 weeks
16
TORCH
Unselected, stage
IIIB/IV
INTACT-1
WJTOG3405
First-SIGNAL
NEJ002
FLEX
BMS 099
SWOG
NCT00946712
Maintenance — Advanced
SATURN
EGFR
676
4
9
10
14
15
1
Related documents